⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GMAB News
Genmab A/S ADS
MHRA Grants Marketing Authorisation to TIVDAK® ▼ (tisotumab vedotin) for the Treatment of Recurrent or Metastatic Cervical Cancer with Disease Progression On or After Systemic Therapy
globenewswire.com
GMAB
NICE Recommends TIVDAK®▼ (tisotumab vedotin) for the Treatment of Eligible Recurrent or Metastatic Cervical Cancer Patients with Disease Progression On or After Systemic Therapy
globenewswire.com
GMAB
Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
globenewswire.com
GMAB
Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
businesswire.com
GMAB
Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
globenewswire.com
GMAB
Capital Increase in Genmab as a Result of Employee Warrant Exercise
globenewswire.com
GMAB
Major Shareholder Announcement
globenewswire.com
GMAB
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
globenewswire.com
GMAB
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
businesswire.com
GMAB
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
globenewswire.com
GMAB